Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study will combine two therapies to treat patients with unresectable hepatocellular
carcinoma; sorafenib, and drug eluting beads delivered intra-arterially. The purpose of the
study is to establish the safety and the effectiveness of the combination therapy. The
investigators hypothesize that the combination of the two therapies will not result in
greater toxicities to patients than that expected for either therapy given alone.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Yale University